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Background: The interaction between clopidogrel and proton pump inhibitors (PPIs)
has not been examined using time-varying drug exposure ascertainment among patients
treated with coronary stents. We examined whether PPI use modified the association
between clopidogrel use and major adverse cardiovascular events (MACE) after
coronary stent implantation.
Methods: We conducted this population-based cohort study in Western Denmark
(population 3 million) using medical databases. We identified all 13,001 patients with
coronary stent implantation between 2002 and 2005 and ascertained their
comorbidities. During the recommended 12-month postintervention treatment period,
we tracked use of clopidogrel and PPI and the rate of MACE. We used Cox regression
to compute hazard ratios, controlling for potential confounders.
Results: The rate of MACE was 154 per 1000 person years for concomitant clopidogrel
and PPI use, 104 for clopidogrel without PPI use, 267 for PPI without clopidogrel use,
and 263 for no use of either drug. The adjusted hazard ratio for MACE comparing
clopidogrel use with non-use was 0.57 (95% confidence interval: 0.44-0.74) among
PPI users and 0.47 (95% confidence interval: 0.42-0.53) among PPI non-users, yielding
an interaction effect (i.e., relative rate increase) of 1.20 (95% confidence interval: 0.91-
1.58). The adjusted hazard ratio for MACE, comparing PPI use with non-use, was 1.40
(95% confidence interval: 1.17-1.68) among clopidogrel users and 1.16 (95%
confidence interval: 0.95-1.43) among clopidogrel non-users.
Conclusion: Clopidogrel use was associated with a markedly reduced rate of MACE
within 12 months after coronary stent implantation, independent of PPI use. PPI use
did not modify the protective effect of clopidogrel substantially, but was associated
with MACE itself.
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Intervention: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
Francesco Pelliccia1, Giuseppe Marazzi2, Vincenzo Pasceri1, Alessio Arrivi3,
Gaetano Tanzilli3, Enrico Mangieri3, Carlo Gaudio3, Giuseppe Mercuro4
1San Filippo Neri Hospital, Rome, Italy; 2San Raffaele Hospital, Rome, Italy;
3University La Sapienza, Rome, Italy; 4University of Cagliari, Cagliari, Italy
Background: Ranolazine is a novel antianginal drug that reduces intracellular sodium
and calcium accumulation during ischemia thus limiting ischemic injury. It remains
unknown, however, if the drug can play a role in the pathophysiology of small
myocardial infarctions after percutaneous coronary intervention (PCI). Aim of this
study was to verify in a randomized study if pre-treatment with ranolazine before PCI
has any protective effect.
Methods: Fifty patients with stable angina (32 men, age: 55+13 years) scheduled for
elective coronary intervention entered a randomized, double-blind, placebo-controlled
pilot trial. For 7 days prior to the procedure, 25 patients were assigned to receive
ranolazine (500 mg twice daily) and 25 patients had placebo. Creatine kinase-MB,
troponin-I and myoglobin levels were measured at baseline and at 8 and 24 hours post
procedure.
Results: Comparison between the two groups did not show any difference in age, sex,
risk factors, cardiac function, and extension of coronary artery disease. Also, there was
no difference in any technical aspect of PCI. Detection of markers of myocardial injury
above the upper normal limit was significantly lower in the ranolazine vs placebo
group: 12% vs 35% for creatine kinase-MB (p=0.001), 20% vs 48% for troponin-I
(p=0.0004) and 22% vs 51% for myoglobin (p=0.0005). Myocardial infarction by
creatine kinase-MB determination was less commonly seen after PCI in the ranolazine
than in the placebo-group (5% vs 18%, p=0.025). Postprocedural peak levels of creatine
kinase-MB (2.9+18 vs 7.5+18 ng/mL, p=0.0002) were also significantly lower in the
ranolazine vs placebo group. No significant side effect was reported by the two groups
of patients.
Conclusion: Pretreatment with ranolazine 500 mg twice daily for 7 days significantly
reduced procedural myocardial injury in elective PCI. These findings indicate that
ranolazine may provide a friendly protection to ischemic cardiomyocytes. A multicentre
randomized study is now ongoing and complete results will be available by 2012.
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Long Term Follow Up Of 4 Treatment Strategies in Multivessel Disease
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Background: Multivessel disease (MVD) is present in ±50% of pts at primary PCI
for 1st acute myocardial infarction (AMI). The optimal treatment for significant non-
culprit lesions (NCL) is unclear. We compared long-term clinical outcome of 4 current
treatment strategies for AMI pts with MVD after primary percutaneous intervention
(PCI).
Methods: Of 1911 consecutive pts with AMI referred for primary PCI from 2006 to
2010, MVD was detected in 928 (48%) pts. Pts without prior AMI or bypass surgery
(CABG), shock or resuscitation were included in this analysis (n=856; 44%). At
primary PCI 68 (8%)pts also had PCI for all NCL (1-stage PCI; 66yr, ˛80%).
Scheduled 2-stage PCI was done in 130 (15%) pts (59 yr, ˛78%), 122(14%) pts (64
yr, ˛78%) had planned CABG and 539 (63%) pts (65 yr, ˛72%) had medical
treatment (MT) only. Follow up included mortality, re-AMI, repeat revascularization,
cerebrovascular accidents (CVA) and admission for heart failure.
Results: Pts in the 2-stage PCI group pts were significantly younger, whereas
hypertension was more prevalent in the CABG group. Mortality was 6% in 1-stage
PCI, 1% in 2-stage PCI, 2% in CABG and 5% in MT group at 1 yr (p=0.04). At 3 yr
follow up mortality was comparable in 1-stage PCI (7%), CABG (7%) and MT (8%)
groups, but lower in the 2-stage PCI group (2%; NS). Re-AMI and CVA were
significantly more frequent in the CABG group (9% and 6%) compared to the 1-stage
PCI group (5% and 2%), the 2-stage PCI group (2% and 0%) and the MT group (3%
and 2%; p=0.01 and p=0.02). No differences were found in admission for heart failure
up to 3 yrs.
Conclusion: Of 4 current treatment strategies for AMI pts with MVD, the planned
revascularization groups (2-stage PCI and CABG) had significant better survival
compared to 1-stage PCI or MT groups at 1 yr. Follow up extended up to 4 yr with
Kaplan-Meier survival plots will be presented. The present data support 2-stage PCI
as preferred treatment strategy for AMI patients with MVD. Prospective randomized
studies are needed to confirm these findings and provide tools to optimize long-term
outcome.
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Background: In patients with STEMI of multivessel disease, complete
revascularization for nonculprit lesions is not routinely recommended. The aim of this
study was to compare the clinical outcomes of multivessel disease compared with IRA-
only revascularization in patients undergoing primary PCI for STEMI.
Methods: From the Korean Acute Myocardial Infarction Registry (KAMIR) database,
1,094 STEMI patients with multivessel disease who underwent primary PCI with DES
were enrolled in this study. The patients were divided into two groups: culprit-vessel-
only revascularization (COR, n=986); multivessel revascularization, including non-IRA
(MVR, n=313). The primary endpoint of this study included major adverse cardiac
events (MACE), such as death, myocardial infarction, or target or nontarget lesion
revascularization at one year.
Results: There was no difference in clinical characteristics between the two groups.
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